Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552240 · ClinicalTrials.gov registry record · Phase 4
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
A Phase 4 study of HIV Infections, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 154
- Enrollment target
- 19
- Study locations
NCT00552240: Completed Phase 4 study of HIV Infections, sponsored by Boehringer Ingelheim.
NCT00552240 is a Phase 4 study of HIV Infections that has completed, run by Boehringer Ingelheim. The registered enrollment target is 154 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (65% lower). The trial reports 19 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00552240, a Phase 4 study of HIV Infections, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 154 participants
- Enrollment target
- 19
- Study locations
Study Summary
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
Primary Outcome
VR is defined as HIV viral load of \<50 copies/ml measured at two consecutive visits PRIOR TO Week 48 and without subsequent rebound or change of ARV therapy prior to Week 48.
Conditions Studied
Interventions
- DRUG tenofovir DF 300 mg QD
- DRUG emtricitabine 200 mg QD
- DRUG Nevirapine 200 mg BID
Study Locations (19)
Texas
- 1100.1512.30 Boehringer Ingelheim Investigational Site - Dallas
- 1100.1512.19 Boehringer Ingelheim Investigational Site - Fort Worth
- 1100.1512.16 Boehringer Ingelheim Investigational Site - Houston
- 1100.1512.24 Boehringer Ingelheim Investigational Site - Houston
Florida
- 1100.1512.17 Boehringer Ingelheim Investigational Site - Fort Lauderdale
- 1100.1512.14 Boehringer Ingelheim Investigational Site - Orlando
- 1100.1512.23 Boehringer Ingelheim Investigational Site - Vero Beach
New Jersey
- 1100.1512.11 Boehringer Ingelheim Investigational Site - Neptune City
- 1100.1512.25 Boehringer Ingelheim Investigational Site - Newark
- 1100.1512.18 Boehringer Ingelheim Investigational Site - Somers Point
California
- 1100.1512.28 Boehringer Ingelheim Investigational Site - Beverly Hills
- 1100.1512.20 Boehringer Ingelheim Investigational Site - Los Angeles
Colorado
- 1100.1512.15 Boehringer Ingelheim Investigational Site - Denver
District of Columbia
- 1100.1512.26 Boehringer Ingelheim Investigational Site - Washington D.C.
Illinois
- 1100.1512.29 Boehringer Ingelheim Investigational Site - Maywood
North Carolina
- 1100.1512.22 Boehringer Ingelheim Investigational Site - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2007-09 |
| Phase | Phase 4 |
What the finished NCT00552240 record still lists
NCT00552240 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (65% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which tenofovir DF 300 mg QD is the first listed.
NCT00552240 lists 19 locations in 11 states (Texas, Florida, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00552240 about?
NCT00552240 is a clinical study titled "Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)". The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
What is the current status of trial NCT00552240?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 154 participants. The study started on 2007-09.
What conditions does trial NCT00552240 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00552240?
The interventions under investigation include: tenofovir DF 300 mg QD (DRUG), emtricitabine 200 mg QD (DRUG), Nevirapine 200 mg BID (DRUG).
Who is sponsoring clinical trial NCT00552240?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00552240 being conducted?
This trial has 19 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00552240's enrollment target sits among peer trials
154 209th of 542 higher than 334 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia